LASEROPTEK Co., Ltd.'s PicoLOtm Picosecond Nd:YAG Laser Receives FDA 510(k) Clearance for Use in Dermatology and General and Plastic Surgery

SEOUL, Republic of Korea, Feb.12, 2019 /PRNewswire/ -- LASEROPTEK Co., Ltd., a developer and manufacturer of world class laser devices for aesthetic and medical dermatology applications, is pleased to announce its PicoLO picosecond Nd:YAG laser recently received U.S. Food and Drug Administration 510(k) clearance for use in Dermatology and General and Plastic Surgery.

PicoLO generates high peak power and consistent picosecond pulse duration producing the strongest photomechanical forces within the skin to quickly and effectively breakdown and fragment pigments such as those found in tattoos. In addition, PicoLO incorporates LASEROPTEK's patented Diffractive Optical Element (DOE) fractional technology consistently creating Laser-induced Optical Breakdown (LIOB) in the dermis even at low power.

This efficient combination of photomechanical effect and LIOB gives PicoLO a significant point of difference with picosecond lasers on the market and delivers numerous advantages to both patients and providers.

"Exceptionally stable energy output and picosecond pulse duration are key technological developments integrated into PicoLO further distancing it from the competition. High stability in both laser output and pulse duration is central to delivering consistently efficacious treatment outcomes while simultaneously minimizing patient discomfort," according to C.J. Lee, CEO of LASEROPTEK.

"Shortly after receiving 510(k) clearance for our LOTUS III^TM, multi-pulsed Er:YAG laser at the end of 2018, the PicoLO clearance will significantly increase LaserOptek sales in the U.S. market. Both LOTUS III and PicoLO are well received in multiple international markets and we are now in the process of establishing an exclusive, full-service dealer network in North America. I encourage anyone who sells, services and provides clinical education to the aesthetic and medical dermatology and plastic surgery markets to contact us as soon as possible," added Mr. Lee. "PicoLO's technology-rich DNA in combination with LASEROPTEK's world class technical and clinical support will garner the attention of dealers, physicians and patients."

To learn more about PicoLO, LOTUS III and the entire suite of LASEROPTEK aesthetic and medical dermatology laser systems, please visit www.laseroptek.com.

PicoLO and LOTUS III will make their post 510(k) clearance North American debut at the 2019 American Academy of Dermatology Conference (AAD) to be held March 1^st thru 5^th in Washington, D.C., U.S.A (Booth # 2461) and at the 2019 American Society for Laser Medicine & Surgery (ASLMS) meeting held March 27^th thru 31^st in Denver, Colorado, U.S.A (Booth # 101).

About LASEROPTEK Co., Ltd.
LASEROPTEK is a global technology-driven device company in aesthetic and medical lasers. Founded in 2000 and with its in-house R&D capabilities, LASEROPTEK introduces safe, stable and high-quality laser systems bringing advanced laser technology and clinical efficacy together.

Media Contact:
Ms. Helena Lee, Marketing Director
[email protected] 
+82-31-8023-5150

SOURCE LASEROPTEK Co., Ltd.